Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
about
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.Signaling pathways as therapeutic targets in biliary tract cancer.Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients.The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.Pimasertib-associated ophthalmological adverse events.BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.
P2860
Q33439312-A6920EC8-4DCA-46B7-A345-4E09CC65F04CQ38747573-01958BA8-7279-4BA7-848E-BA26DE45D840Q38941928-8A43DBE6-66F3-4DAA-9CBE-628CE222E7FAQ46235377-35537F2E-0BC6-418C-9FB9-9D57F00D85DBQ47786514-A0A2576A-5A2D-4EA0-A121-770B92CDB6F0Q48234610-77F696E3-83FA-4308-8848-9AEE87CC9316Q53705974-C20F866F-FA8D-4058-BBF2-DCE6BCC24A73
P2860
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase I study of FOLFIRI plus ...... metastatic colorectal cancer.
@ast
Phase I study of FOLFIRI plus ...... metastatic colorectal cancer.
@en
type
label
Phase I study of FOLFIRI plus ...... metastatic colorectal cancer.
@ast
Phase I study of FOLFIRI plus ...... metastatic colorectal cancer.
@en
prefLabel
Phase I study of FOLFIRI plus ...... metastatic colorectal cancer.
@ast
Phase I study of FOLFIRI plus ...... metastatic colorectal cancer.
@en
P2093
P2860
P50
P356
P1476
Phase I study of FOLFIRI plus ...... metastatic colorectal cancer.
@en
P2093
A Cervantes
B Laffranchi
E Martinelli
E Van Cutsem
O von Richter
T Macarulla
P2860
P2888
P304
P356
10.1038/BJC.2015.144
P407
P577
2015-05-19T00:00:00Z